Publications

BibTex format

@article{Herrera:2019:10.3389/fphar.2019.00578,
author = {Herrera, C},
doi = {10.3389/fphar.2019.00578},
journal = {Frontiers in Pharmacology},
title = {The pre-clinical toolbox of pharmacokinetics and pharmacodynamics: in vitro and ex vivo models},
url = {http://dx.doi.org/10.3389/fphar.2019.00578},
volume = {10},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Prevention strategies against sexual transmission of human immunodeficiency virus (HIV) are essential to curb the rate of new infections. In the absence of a correlate of protection against HIV infection, pre-clinical evaluation is fundamental to facilitate and accelerate prioritization of prevention candidates and their formulations in a rapidly evolving clinical landscape. Characterization of pharmacokinetic (PK) and pharmacodynamic (PD) properties for candidate inhibitors is the main objective of pre-clinical evaluation. in vitro and ex vivo systems for pharmacological assessment allow experimental flexibility and adaptability at a relatively low cost without raising as significant ethical concerns as in vivo models. Applications and limitations of pre-clinical PK/PD models and future alternatives are reviewed in the context of HIV prevention.
AU  - Herrera,C
DO  - 10.3389/fphar.2019.00578
PY  - 2019///
SN  - 1663-9812
TI  - The pre-clinical toolbox of pharmacokinetics and pharmacodynamics: in vitro and ex vivo models
T2  - Frontiers in Pharmacology
UR  - http://dx.doi.org/10.3389/fphar.2019.00578
UR  - http://hdl.handle.net/10044/1/70465
VL  - 10
ER  -

Download

DrCarolinaHerrera

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)